

Date: 12/08/2017



**Vivimed**

To  
BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001  
**BSE - Code : 532660**

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
**NSE- Symbol: VIVIMEDLAB**

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.**

The Board of Directors of the Company at its meeting held on August 12, 2017 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2017 attached herewith;
2. Auditors's Limited Review Report on the Un-audited Financial Statements of the Company for the quarter ended June 30, 2017.

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

**For Vivimed Labs Limited**

  
**SANTOSH VARALWAR**  
**MANAGING DIRECTOR**



**Vivimed Labs Ltd. [Corporate Office]**

CIN: L02411KA1988PLC009465

North End, Road No. 2,

Banjara Hills, Hyderabad, Telangana - 500 034, India.

T +91(0) 40 6608-6608

[contact@vivimedlabs.com](mailto:contact@vivimedlabs.com) | [www.vivimedlabs.com](http://www.vivimedlabs.com)

**VIVIMED LABS LIMITED**  
**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2017**

Rs. in Lacs

Sl. No.	Particulars	Quarter Ended			Previous Year
		30.06.2017	31.03.2017	30.06.2016	ended 31.03.2017
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	<b>Income From Operations</b>				
	<b>Gross Sales</b>	32,275.10	43,668.29	37,288.51	1,46,191.12
	<b>Less Duties</b>	477.67		605.47	
1	Net Sales / Income from Operations (Net of Excise Duty)	31,797.42	43,668.29	36,683.04	1,46,191.12
2	Other Income	265.93	228.47	176.60	805.04
3	<b>Total Revenue (1+2)</b>	<b>32,063.35</b>	<b>43,896.77</b>	<b>36,859.64</b>	<b>1,46,996.16</b>
4	<b>Expenses</b>				
a	Cost of material consumed	12,204.51	11,689.84	16,775.35	56,583.13
b	Purchases of Stock- in- Trade				
c	Changes in inventories of finished goods work in progress and stock-in-Trade	1,542.11	(1,219.08)	418.24	(2,954.62)
d	Employee Benefit Expenses	4,276.56	4,769.60	5,014.77	18,934.31
e	Finance Costs	2,422.98	1,802.78	1,520.84	6,551.77
f	Depreciation and Amortisation Expenses	1,255.60	1,259.68	1,584.40	5,827.75
g	Other Expenses	7,050.78	9,795.87	7,966.50	32,457.24
h	Other Comprehensive (Income)/Losses	76.52		24.52	
	<b>Total Expenses</b>	<b>28,829.06</b>	<b>28,098.69</b>	<b>33,304.62</b>	<b>1,17,399.58</b>
5	<b>Profit/(Loss) before extraordinary items and tax (3-4)</b>	<b>3,234.29</b>	<b>15,798.08</b>	<b>3,555.02</b>	<b>29,596.58</b>
6	Extraordinary items	-	-	-	-
7	<b>Profit/(Loss) before extraordinary items and tax (5-6)</b>	<b>3,234.29</b>	<b>15,798.08</b>	<b>3,555.02</b>	<b>29,596.58</b>
8	Extraordinary items	-	-	-	-
9	<b>Profit/(Loss) before tax (7-8)</b>	<b>3,234.29</b>	<b>15,798.08</b>	<b>3,555.02</b>	<b>29,596.58</b>
10	<b>Tax expenses</b>				
	Current Taxes	843.82	4,222.71	793.61	7,409.46
	Deferred Taxes	-	100.11	-	12.72
		843.82	4,322.82	793.61	7,422.18
11	<b>Profit/(Loss) for the period from continuing operations (9-10)</b>	<b>2,390.47</b>	<b>11,475.26</b>	<b>2,761.41</b>	<b>22,174.40</b>
12	Profit / (Loss) from discontinued operations	-	-	-	-
13	Tax expenses of discontinued operations	-	-	-	-
14	Profit/(Loss) from the discontinued operations(after tax) (12-13)	-	-	-	-
15	<b>Profit/(Loss) for the period /Year</b>	<b>2,390.47</b>	<b>11,475.26</b>	<b>2,761.41</b>	<b>22,174.40</b>
16	Minority Interest	-	-	-	-
17	<b>Net Profit / Loss after taxes and Minority Interest (15-16)</b>	<b>2,390.47</b>	<b>11,475.26</b>	<b>2,761.41</b>	<b>22,174.40</b>
18	Paid up Equity Share Capital	1,639.73	1,620.38	1620.38	1,620.38
19	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	<b>66,969.33</b>	-	<b>66,969.33</b>
20	<b>Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)</b>				
	(a) Basic	2.92	14.00	3.37	27.05
	(b) Diluted	2.86	13.74	3.31	26.55

1. The above Consolidated Audited Financial Results for the Quarter & Year ended 30.06.2017 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 12.08.2017

2. Consolidated Financial Statements have been prepared in accordance with Indian Accounting standards (IndAS) as prescribed under section 133 of the companies Act, 2013 read with the companies (Indian Accounting Standards) Rules, 2015 (as amended). Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Finoso Pharma pvt Limited (ii) Vivimed Speciality chemicals pvt Ltd and its wholly owned foreign subsidiaries viz (i) Vivimed Labs USA, Inc., (ii) Vivimed Labs Mauritius Limited (iii) Vivimed Holdings Limited and its stepdown subsidiaries (iv) Vivimed Labs Europe Limited (v) Vivimed Labs UK Limited, (vi) Vivimed Labs Spain, S.L. (vii) Union Quimico Farmaceutica S.A.U., Spain, (viii) Holliday International Limited, UK & (ix) Uquija Mexico S.A. de C.V.

3. As per IND AS on Segment Reporting, results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR

Place : Hyderabad  
 Date : 12.08.2017



## VIVIMED LABS LIMITED

## SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED

Rs.in Lacs

Particulars	3 Months Ended			FY 17
	30.06.2017	31.03.2017	30.06.2016	31-03-2017
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	5,395.36	21,482.64	7,998.67	45,152.82
b.Pharma Business	26,402.06	22,185.65	28,684.37	1,01,038.30
<b>Total</b>	<b>31,797.42</b>	<b>43,668.29</b>	<b>36,683.04</b>	<b>1,46,191.12</b>
Less, Inter Segment Revenue				
<b>Net sales / Income from Operations</b>	<b>31,797.42</b>	<b>43,668.29</b>	<b>36,683.04</b>	<b>1,46,191.12</b>
<b>2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>				
a.Speciality Chemicals Business	1,526.74	15,301.30	1,519.15	21,710.76
b.Pharma Business	4,130.53	2,299.55	3,556.71	14,437.59
<b>Total</b>	<b>5,657.27</b>	<b>17,600.85</b>	<b>5,075.86</b>	<b>36,148.35</b>
Less: 1.Interest	2,422.98	1,802.78	1,520.84	6,551.77
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
<b>Total Profit Before Tax</b>	<b>3,234.29</b>	<b>15,798.08</b>	<b>3,555.02</b>	<b>29,596.58</b>
<b>3. Capital Employed</b>				
a.Speciality Chemicals Business	99,494.26	99,114.25	78,275.46	99,114.25
b.Pharma Business	65,503.29	63,492.83	79,728.15	63,492.83
	<b>1,64,997.55</b>	<b>1,62,607.08</b>	<b>1,58,003.61</b>	<b>1,62,607.08</b>
a.Segment Assets	2,07,252.29	2,06,552.26	2,05,232.25	2,06,552.26
b.Segment Liabilities	1,35,262.55	1,34,162.55	1,32,263.59	1,34,162.55

Place : Hyderabad  
Date : 12.08.2017



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR

**VIVIMED LABS LIMITED**  
**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2017**

Rs. in Lacs

Sl. No.	Particulars	Quarter Ended			Previous Year ended
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		(UnAudited)	(Audited)	(UnAudited)	(Audited)
	<b>Income From Operations</b>				
1	Gross Sales	7,113.27	22,608.42	11,498.73	56,983.78
	Less : Duties	477.67	-	605.47	-
		<b>6,635.60</b>	<b>22,608.42</b>	<b>10,893.26</b>	<b>56,983.78</b>
2	Other Income	35.07	164.25	0.70	234.12
3	<b>Total Revenue (1+2)</b>	<b>6,670.67</b>	<b>22,772.67</b>	<b>10,893.96</b>	<b>57,217.90</b>
4	<b>Expenses</b>				
a	Cost of material consumed	2,552.72	3,347.50	6,198.30	18,219.17
b	Purchases of Stock-in- Trade	-	-	-	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(119.08)	463.63	(752.54)	(226.08)
d	Employee Benefit Expenses	693.83	1,120.54	1,085.24	4,159.88
e	Finance Costs	1,214.95	1,431.92	1,265.81	5,354.99
f	Depreciation and Amortisation Expenses	447.07	505.67	750.10	2,683.21
g	Other Expenses	1,600.67	2,889.07	2,119.50	8,882.53
h	Other Comprehensive (Income)/Losses - Ind AS	76.52	-	24.52	-
	<b>Total Expenses</b>	<b>6,466.68</b>	<b>9,758.33</b>	<b>10,690.92</b>	<b>39,073.70</b>
5	<b>Profit/(Loss) before exceptional items and tax (3-4)</b>	<b>203.99</b>	<b>13,014.34</b>	<b>203.04</b>	<b>18,144.20</b>
6	Exceptional items	-	-	-	-
7	<b>Profit/(Loss) before extraordinary items and tax (5-6)</b>	<b>203.99</b>	<b>13,014.34</b>	<b>203.04</b>	<b>18,144.20</b>
8	Extraordinary items	-	-	-	-
9	<b>Profit/(Loss) before tax (7-8)</b>	<b>203.99</b>	<b>13,014.34</b>	<b>203.04</b>	<b>18,144.20</b>
10	Tax Expenses				
	Current Taxes	40.80	3,528.75	54.64	4,812.11
	Deferred Taxes	-	64.19	-	64.19
	Tax Expenses	40.80	3,592.94	54.64	4,876.30
11	<b>Profit/(Loss) for the period from continuing operations (9-10)</b>	<b>163.19</b>	<b>9,421.40</b>	<b>148.40</b>	<b>13,267.90</b>
12	Profit/(Loss) from discontinued operations	-	-	-	-
13	Tax expenses of discontinued operations	-	-	-	-
14	Profit/(Loss) from the discontinued operations(after tax) (12-13)	-	-	-	-
15	<b>Profit/(Loss) for the period /Year</b>	<b>163.19</b>	<b>9,421.40</b>	<b>148.40</b>	<b>13,267.90</b>
16	Minority Interest	-	-	-	-
17	<b>Net Profit / Loss after taxes and Minority Interest (15-16)</b>	<b>163.19</b>	<b>9,421.40</b>	<b>148.40</b>	<b>13,267.90</b>
18	Paid up Equity Share Capital	1,639.73	1,620.38	1,620.38	1,620.38
19	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	49,491.17
20	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)				
	(a) Basic	0.20	11.49	0.18	16.38
	(b) Diluted	0.20	11.28	0.18	15.89

1. The above Standalone Audited Financial Results for the Quarter ended June 30, 2017 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 12.08.2017. The Financial results are prepared in accordance with the Indian Accounting standards(IndAS) as prescribed under section 133 of the companies Act,2013 read with the companies (Indian Accounting Standards)Rules,2015(as amended)

2.As per IndAS , results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

3.Corresponding numbers of previous period / year have been regrouped, wherever necessary.

4.The QOQ-Q1 FY 17 is regrouped and reclassified on account of amalgamation of subsidiaries hence not comparable to the earlier published results.

Place : Hyderabad  
Date : 12.08.2017



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR



**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED**

Rs. in Lacs

Particulars	Quarter Ended			YEAR ENDED
	30.06.2017	31.03.2017	30.06.2016	31.03.2017
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1. Segment Revenue</b> <i>(net sales/income from each segment should be disclosed under this head)</i>				
a.Speciality Chemicals Business	1,660.95	17,871.98	5,430.61	32,030.31
b.Pharma Business	4,974.65	4,736.44	5,462.65	24,953.46
<b>Total</b>	<b>6,635.60</b>	<b>22,608.42</b>	<b>10,893.26</b>	<b>56,983.78</b>
Less, Inter Segment Revenue				
<b>Net sales / Income from Operations</b>	<b>6,635.60</b>	<b>22,608.42</b>	<b>10,893.26</b>	<b>56,983.78</b>
<b>2.Segment Results (Profit) (+) / Loss (-)</b> <i>before tax and interest from each segment</i>				
a.Speciality Chemicals Business	160.33	13,383.23	1,178.47	19,398.06
b.Pharma Business	1,258.61	1,063.03	290.37	4,101.12
<b>Total</b>	<b>1,418.94</b>	<b>14,446.26</b>	<b>1,468.85</b>	<b>23,499.18</b>
Less: 1.Interest	1,214.95	1,431.92	1,265.81	5,354.98
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
<b>Total Profit Before Tax</b>	<b>203.99</b>	<b>13,014.34</b>	<b>203.04</b>	<b>18,144.20</b>
<b>3. Capital Employed</b>				
a.Speciality Chemicals Business	77,330.89	77,550.04	74,972.41	77,550.04
b.Pharma Business	39,256.25	38,873.91	46,135.87	38,873.91
	<b>1,16,587.14</b>	<b>1,16,423.95</b>	<b>1,21,108.28</b>	<b>1,16,423.95</b>
<b>4.</b>				
a.Segment Assets	1,37,526.17	1,36,429.14	1,32,526.17	1,36,429.14
b. Segment Liabilities	82,412.35	81,517.55	79,219.26	81,517.55

Place : Hyderabad

Date : 12.08.2017



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR



**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

To  
The Board of Directors  
Vivimed Labs Limited  
Hyderabad

**Limited Review Report for the quarter ended 30<sup>th</sup> June, 2017 on consolidated unaudited financials:**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of M/s. Vivimed Labs Limited for the quarter ended 30<sup>th</sup> June, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 12<sup>th</sup> August, 2017. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

  
A Krishna Rao  
Partner  
M.No. 020085



Place: Hyderabad  
Date: 12<sup>th</sup> August 2017





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

To  
The Board of Directors  
Vivimed Labs Limited  
Hyderabad

**Limited Review Report for the quarter ended 30<sup>th</sup> June, 2017**

1. We have reviewed the accompanying statement of unaudited financial results of M/s. Vivimed Labs Limited for the quarter ended 30<sup>th</sup> June, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 12<sup>th</sup> August, 2017. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

  
A Krishna Rao  
Partner  
M.No. 020085



Place: Hyderabad  
Date: 12<sup>th</sup> August 2017